Pharmacokinetics of Immunoglobulin Administered via Intravenous or Subcutaneous Routes

Immunology and Allergy Clinics of North America

Volumn 28, Issue 4, 2008, Pages 803-819

  Bonilla, Francisco A ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Immunoglobulin; Intravenous; Pharmacokinetics; Subcutaneous

Indexed keywords

CARIMUNE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; PRIVIGEN; TETANUS TOXOID; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; AREA UNDER THE CURVE; BONE MARROW TRANSPLANTATION; BURN; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; HUMAN; HUMORAL IMMUNITY; HYPOPROTEINEMIA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; IMMUNOTHERAPY; INFECTION; LOW DRUG DOSE; MULTIPLE MYELOMA; NEWBORN; NEWBORN SEPSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SINGLE DRUG DOSE; SUBSTITUTION THERAPY; X LINKED AGAMMAGLOBULINEMIA;

ADULT; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; INFUSION PUMPS; INJECTIONS, SUBCUTANEOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MULTIPLE MYELOMA; SEPSIS;

EID: 53849119869     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2008.06.006     Document Type: Review

References (49)

1. Orange J.S., Hossny E.M., Weiler C.R., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117 (2006) S525-S553
2. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 112 (2004) 1-7
3. Waldmann T.A., and Strober W. Metabolism of immunoglobulins. Prog Allergy 13 (1969) 1-110
4. Waldmann T.A., Strober W., and Blaese R.M. Variations in the metabolism of immunoglobulins measured by turnover rates. In: Merler E. (Ed). Immunoglobulins (1970), National Academy of Sciences, Washington, DC 33-51
5. Brambell F.W., Hemmings W.A., and Morris I.G. A theoretical model of gamma-globulin catabolism. Nature 203 (1964) 1352-1354
6. Junghans R.P., and Anderson C.L. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A 93 (1996) 5512-5516
7. Simister N.E., and Mostov K.E. An Fc receptor structurally related to MHC class I antigens. Nature 337 (1989) 184-187
8. Leach J.L., Sedmak D.D., Osborne J.M., et al. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol 157 (1996) 3317-3322
9. Roopenian D.C., and Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7 (2007) 715-725
10. Sachs U.J., Socher I., Braeunlich C.G., et al. A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter. Immunology 119 (2006) 83-89
11. Waldmann T.A., and Terry W.D. Familial hypercatabolic hypoproteinemia: a disorder of endogenous catabolism of albumin and immunoglobulin. J Clin Invest 86 (1990) 2093-2098
12. Wani M.A., Haynes L.D., Kim J., et al. Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci U S A 103 (2006) 5084-5089
13. Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 45 (2005) 490-497
14. Koleba T., and Ensom M.H. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy 26 (2006) 813-827
15. Alyanakian M.A., Bernatowska E., Scherrmann J.M., et al. Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes. Vox Sang 84 (2003) 188-192
16. Ballow M., Berger M., Bonilla F.A., et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang 84 (2003) 202-210
17. Berger M. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. J Clin Immunol 27 (2007) 628-633
18. Berger M., and Pinciaro P.J. Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 24 (2004) 389-396
19. Borte M., Davies S.V., Touraine J.-L., et al. Clinical properties of a novel liquid intravenous immunoglobulin: studies of patients with immune thrombocytopenic purpura and primary immunodeficiencies. Transfus Med Hemother 31 (2004) 126-134
20. Church J.A., Leibl H., Stein M.R., et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol 26 (2006) 388-395
21. Ochs H.D., and Pinciaro P.J. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 24 (2004) 309-314
22. Privigen. Prescribing information (2008), CSL Behring, King of Prussia (PA)
23. Schiff R.I., and Rudd C. Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency. J Clin Immunol 6 (1986) 256-264
24. Eijkhout H.W., van Der Meer J.W., Kallenberg C.G., et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial. Ann Intern Med 135 (2001) 165-174
25. Mankarious S., Lee M., Fischer S., et al. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med 112 (1988) 634-640
26. Shirani K.Z., Vaughan G.M., McManus A.T., et al. Replacement therapy with modified immunoglobulin G in burn patients: preliminary kinetic studies. Am J Med 76 (1984) 175-180
27. Hansbrough J.F., Miller L.M., Field Jr. T.O., et al. High dose intravenous immunoglobulin therapy in burn patients: pharmacokinetics and effects on microbial opsonization and phagocytosis. Pediatr Infect Dis J 7 (1988) S49-S56
28. Chirico G., Rondini G., Plebani A., et al. Intravenous gammaglobulin therapy for prophylaxis of infection in high-risk neonates. J Pediatr 110 (1987) 437-442
29. Kinney J., Mundorf L., Gleason C., et al. Efficacy and pharmacokinetics of intravenous immune globulin administration to high-risk neonates. Am J Dis Child 145 (1991) 1233-1238
30. Kyllonen K.S., Clapp D.W., Kliegman R.M., et al. Dosage of intravenously administered immune globulin and dosing interval required to maintain target levels of immunoglobulin G in low birth weight infants. J Pediatr 115 (1989) 1013-1016
31. Noya F.J., Rench M.A., Courtney J.T., et al. Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates. Pediatr Infect Dis J 8 (1989) 759-763
32. Noya F.J., Rench M.A., Garcia-Prats J.A., et al. Disposition of an immunoglobulin intravenous preparation in very low birth weight neonates. J Pediatr 112 (1988) 278-283
33. Weisman L.E., Fischer G.W., Hemming V.G., et al. Pharmacokinetics of intravenous immunoglobulin (sandoglobulin) in neonates. Pediatr Infect Dis 5 (1986) S18-S188
34. Weisman L.E., Fischer G.W., Marinelli P., et al. Pharmacokinetics of intravenous immunoglobulin in neonates. Vox Sang 57 (1989) 243-248
35. Weisman L.E., Stoll B.J., Kueser T.J., et al. Intravenous immune globulin prophylaxis of late-onset sepsis in premature neonates. J Pediatr 125 (1994) 922-930
36. Jenson H.B., and Pollock B.H. Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis. Pediatrics 99 (1997) E2
37. Ohlsson A., and Lacy J.B. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev (2000) CD000361
38. Groothuis J.R., Levin M.J., Rodriguez W., et al. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group. Antimicrob Agents Chemother 35 (1991) 1469-1473
39. Bosi A., De Majo E., Guidi S., et al. Kinetics of anti-CMV antibodies after administration of intravenous immunoglobulins to bone marrow transplant recipients. Haematologica 75 (1990) 109-112
40. Cottler-Fox M., Lynch M., Pickle L.W., et al. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels. Bone Marrow Transplant 8 (1991) 27-33
41. Hagenbeek A., Brummelhuis G.J., Donkers A., et al. Rapid clearance of cytomegalovirus-specific IgG after repeated intravenous infusions of human immunoglobulin into allogeneic bone marrow transplant recipients. J Infect Dis 155 (1987) 897-902
42. Rand K.H., Gibbs K., Derendorf H., et al. Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. J Clin Pharmacol 31 (1991) 1151-1154
43. Rand K.H., Houck H., Ganju A., et al. Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients. Bone Marrow Transplant 4 (1989) 679-683
44. Chapel H.M., Hargreaves R., Lee M., et al. Intravenous immunoglobulin therapy in patients with multiple myeloma. Immunodeficiency 4 (1993) 77-78
45. Sklenar I., Schiffman G., Jonsson V., et al. Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma. Oncology 50 (1993) 466-477
46. Smith G.N., Griffiths B., Mollison D., et al. Uptake of IgG after intramuscular and subcutaneous injection. Lancet 1 (1972) 1208-1212
47. Waniewski J., Gardulf A., and Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 14 (1994) 90-97
48. Ochs H.D., Gupta S., Kiessling P., et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 26 (2006) 265-273
49. Gustafson R., Gardulf A., Hansen S., et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol 152 (2008) 274-279